CLEC12A and acute myeloid leukemia: A phase I dose escalation trial (NCT03298516) investigated the DCLL9718S, a humanized antibody targeting CLL1 linked to PBD, in R/R ALML, either as a single agent or in combination with aza, in previously untreated AML unsuitable for intensive therapy.